Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... quarter of calendar 2010, and will initiate our Phase III program for Stedivaze for cardiac stress testing, shortly. During the quarter, we again demonstrated our ability to secure ... as well as royalties related to the commercialization of multiple myeloma and other B-cell cancer treatments Reported a 51% increase in FAMILION genetic testing gross ... Multiple Myeloma, Myeloma, Oncology, Pharmaceutical Business, Pharmaceutical Company, Therapy, Treatment, Clinical Data Inc. This article was prepared by Biotech ...
2009 NOV 23 ... Inside Us All Source: Derma Sciences, Inc. TEWKSBURY, Mass.--Are you at Risk for Sudden Cardiac Arrest? Source: Cambridge Heart BERLIN, N.J.--A Sick Day Survival Kit Can Make Even a ... Cardiology, Diabetes, Diabetic Foot, Drug Development, Endocrinology, Foot Ulcer, Stem Cell Research, Therapy, Treatment, Ulcer, Wellness, Business Wire. This article ...
2009 NOV 16 ... diseases. ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today, ISHLT has over 2200 members from over 45 countries, representing over ... of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy; Importantly, the Journal also serves as a medium of communication ...
2009 NOV 16 ... accumulation. The clinical consequences of iron overload are progressive liver damage, cardiac disease, and endocrine disorders,which can be fatal." "Nurses have a ... to treat chronic anemias, such as myelodysplastic syndromes, thalassemia, and sickle-cell disease, are at risk of iron accumulation. The clinical consequences of iron overload ... a study from the United States, "Receiving recurring blood transfusions as supportive therapy to treat chronic anemias, such as myelodysplastic syndromes, thalassemia, and ...
2009 NOV 16 ... with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Sudden death, stroke, and myocardial ... Pharmaceutical Corporation 862-778-8656 (office) 201-400-1854 (cell) michael.billings@novartis.com e-mail: ... treatment. Periodic monitoring of CBC with differential is advised during prolonged therapy. The most common adverse events (at least 5% and twice the incidence of ...
2009 NOV 16 ... of capillary density and inhibition of LV fibrosis. Dual-label immunohistochemistry for cardiac troponin-I and human nuclear antigen (HNA) demonstrated that human cardiomyocytes (CMCs) ... that expression of human-specific genes of CMCs, smooth muscle cells, and endothelial cell markers in infarcted myocardium were significantly augmented in USSC-treated animals ... Biotechnology, Biotherapy, Blood Transfusion, Cardiology, Cardiovascular, Cell Therapy, Cord Blood, Echocardiography, Fibrosis, Heart Attack, Hematology, Hepatology, ...
2009 NOV 23 ... IS reduction (39.1 +/- A 3.9% HFD-STD vs. 40.0 +/- A 5.3% HFD, P> 0.05). Serum and cardiac adiponectin levels were unaltered by rimonabant treatment. HL-1 cell death was not ... Medical Device, Myocardial Infarction, Neurology, Obesity, Pharmaceuticals, Reperfusion, Therapy, Transfusion Medicine, Treatment. This article was prepared by Pain & ...
2009 NOV 23 ... and protein expression are induced by oxidative stress (0.2 mM H2O2) in neonatal rat cardiac myocytes. In other cells, constitutive Mdm2 expression is regulated by the P1 promoter ... and hence its own degradation." "Although extensively studied in cell lines, relatively little is known about Mdm2 expression in heart where oxidative stress ... Medical Device, Pharmaceuticals, Protein Expression, Proteins, Proteomics, Reperfusion, Therapy, Transfusion Medicine, Treatment, University of London, Imperial College. ...
2009 NOV 23 ... risk factors recent evidence indicates direct action's of testosterone on cardiac tissue." "However, the impact on human cardiac L-type calcium channels ... from patients undergoing heart transplantation. Patch-clamp experiments in whole-cell. configuration were performed to evaluate the effect of dihydrotestosterone on cardiac ... Drugs, Endocrine, Heart Transplant, Organ Transplant, Pharmaceuticals, Testosterone, Therapy, Transplantation, Treatment, University of Cologne. This article was ...
2009 NOV 23 ... "The positive effects of natural antioxidant foods on the prevention of DXR-induced cardiac injury could not be clearly shown on the basis of antioxidant enzymes. However, the ... treatment of several childhood malignancies. During treatment, cardiotoxicity caused by cell damage due to the free oxygen radicals that are generated is a major limiting factor," ... Research, Doxorubicin Hydrochloride, Drugs, Pharmaceuticals, Pharmacology, Physiology, Therapy, Treatment. This article was prepared by Biotech Business Week editors from ...
2009 NOV 23 ... 1 year of the EPC capturing stent as compared to DES. TLF is defined as the composite of cardiac death, myocardial infarction, and clinically driven target lesion revascularization. In ... accelerated endothelial coverage of the stent surface, the endothelial progenitor cell (EPC) capturing stent has shown its safety and efficacy in the HEALING observational ... Progenitor Cells, Restenosis, Stem Cell Research, Surgery, Surgical Technology, Therapy, Thrombosis, Treatment, University of Amsterdam. This article was prepared ...
2009 NOV 23 ... According to a study from Heidelberg, Germany, "During acute rejection of cardiac transplants endothelial cell-leukocyte interaction fuelled by co-stimulatory molecules ... Heart Transplant, Immunology, Interferon, Interferon Gamma, Organ Transplant, Therapy, Transplantation, Treatment, University of Heidelberg. This article was ...
2009 NOV 16 ... was previously shown to be upregulated at very early stages of the pathogenesis in the cardiac mouse model. Although no active hit has been identified, the present study demonstrates ... report. "In the absence of measurable catalytic function for frataxin, a cell-based assay is required for HTS assay. Using a targeted ribozyme strategy in murine ... Nervous System Disease, Drug Development, Drug Discovery, Friedreich Ataxia, Gene Therapy, Genetic Diseases, Genetics, Neurology, Pharmaceuticals, Pharmacological, Treatment, ...
2009 NOV 29 ... during the wait for a donor heart," said Dr. Jeffrey Dreyer, medical director of cardiac transplantation at Texas Children's Hospital.According to Morales, De ... Morales said..The Thoratec HeartMate II, about the size of two "D" cell batteries laid end-to-end, received U. S. Food and Drug Administration approval on April ... to the movies. He'll be coming to Texas Children's for follow-up visits and physical therapy. We're keeping a close eye on him while he waits for a donor heart," Morales ...
2009 NOV 23 ... during the wait for a donor heart," said Dr. Jeffrey Dreyer, medical director of cardiac transplantation at Texas Children's Hospital. According to Morales, De ... awaiting transplant. The Thoratec HeartMate II, about the size of two "D" cell batteries laid end-to-end, received U.S. Food and Drug Administration approval on April ... to the movies. He'll be coming to Texas Children's for follow-up visits and physical therapy. We're keeping a good eye on him while he waits for a donor heart," he said. ...
2009 NOV 23 ... is considerably less toxic than inorganic arsenic, particularly with regard to cardiac toxicity. Phase I and Phase II testing of the intravenous form of darinaparsin in solid ... from the trial with IV-administered darinaparsin in lymphoma, particularly peripheral T-cell lymphoma ("PTCL"), were reported at the American Society of Clinical Oncology (ASCO) ... Sunitinib Maleate, Sutent, Synovial Sarcoma, Testicular Cancer, Testicular Diseases, Therapy, Treatment, U.S. Food and Drug Administration, Urology, ZIOPHARM Oncology Inc. ...
2009 NOV 23 ... is considerably less toxic than inorganic arsenic, particularly with regard to cardiac toxicity. Phase I and Phase II testing of the intravenous form of darinaparsin in solid ... results in lymphoma with the intent of conducting a registration trial in peripheral T-cell lymphoma, also as early as the first half of 2010. The oral darinaparsin Phase I trials ... Pre-Trials Research, Regulatory Actions, Sarcoma, Soft Tissue Sarcoma, Therapies, Therapy, Treatment, U.S. Food and Drug Administration, Women's Health, ZIOPHARM Oncology Inc. ...
